Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model

American Journal of Pathology

Volumn 154, Issue 2, 1999, Pages 543-551

  Jongsma, Johan ^a,c   Oomen, Monique H ^a   Noordzij, Marinus A ^a   Van Weerden, Wytske M ^a   Martens, Gerard J M ^b   Van Der Kwast, Theodorus H ^a   Schröder, Fritz H ^a   Van Steenbrugge, Gert J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CHROMOGRANIN A; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT; XENOGRAFT;

EID: 0032914651     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65300-X     Document Type: Article

References (48)

1. Abrahamsson PA: Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996, 6:3-8
2. Bonkhoff H, Stem U, Remberger K: Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma is postmitotic cells. Hum Pathol 1995, 26:167-170
3. di-Sant'Agnese PA: Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992, 23:287-296
4. di-Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma. Cancer Suppl 1995, 75:1850-1859
5. Noordzij MA, van Steenbrugge GJ, van der Kwast T, Schröder FH: Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res 1995, 22:333-341
6. Noordzij MA, van der Kwast T, van Steenbrugge GJ, Hop WJC, Schröder FH: The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995, 62:252-258
7. Abrahamsson P-A, Wadström LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 1986, 181:675-683
8. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE: Characterization of neuroendocrine differentiation in numan benign prostate and prostatic adenocarcinoma. Cancer 1993, 71:3952-3965
9. Abdul M, Logothetis CJ, Hoosein NM: Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995, 154:247-250
10. Seuwen K, Pouyssegur J: Serotonin as a growth factor. Biochem Pharmacol 1990, 39:985-990
11. Aprikian AG, Han K, Chevalier S, Baznet M, Viallet J: Bombesin specifically induces intracellular calcium mobilization via gastrin releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996, 16:287-296
12. Mack D, Hacker GW, Hauser-Kronberger C, Frick J, Dietze O: Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. Eur J Cancer 1997, 33:317-318
13. Zia H, Hida T, Jakowlev S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I, Moody TW: Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res 1996, 56:3486-3489
14. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guyarro LG, Prieto JC: Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptors in human benign hyperplastic prostate. Endocrinology 1996, 137:2815-2822
15. Iwamura M, Wu G, Abrahamsson PA, Di-Sant'Agnese PA, Cockett ATK, Deftos LJ: Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994, 43:667-674
16. Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rosette J, Schalken J: Prostatic neuroendocrine cells have a unique keratin expression and do not express Bcl-2. Am J Pathol 1997, 151:1759-1765
17. Abrahamsson PA, Falkmer S, K FÖ, Grimelius L: The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract 1989, 185:373-380
18. Hendy GN, Bevan S, Mattei MG, Mouland AJ: Chromogranin A. Clin Invest Med 1995, 18:47-65
19. Schmidt KW, Helpap B, Totsch M, Kirchmair R, Dockhorn-Dworniczak B, Bocker W, Fischer-Colbrie R: Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate. Histopathology 1994, 24:233-239
20. Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, van der Kwast T: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993, 100:393-398
21. Cohen RJ, Cooper K, Haffejee Z, Robinson E, Becker PJ: Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology. 1995, 27:229-232
22. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994, 25:42-46
23. Bonkhoff H, Stein U, Remberger K: The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994, 24:114-118
24. Cohen MK, Arber DA, Coffield S, Keegan GT, McClintock J, Speights VO: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994, 74:1899-1903
25. Colombel M, Olsson CA, Ng PY, Buttyan R: Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992, 52:4313-4319
26. Holthuis JCM, Martens GJM: The neuroendocrine proteins secretogranin II and III are regionally conserved and coordinately expressed with proopiomelanocortin in Xenopus intermediate pituitary. J Neurochem 1996, 66:2248-2256
27. Smeekens SP, Montag AG, Thomas G, Albiges-Rizo C, Carrol R, Benig M, Philips LA, Martin S, Ohagi S, Gardner P, Swift H, Steiner DF: Proinsulin processing by the sutilisin-related proprotein convertases furin. PC2, and PC3. Proc Natl Acad Sci USA 1992, 89:8822-8826
28. Tucker JD, Dhanvantari S, Brubaker PL: Proglucagon processing in islet and intestinal cell lines. Regul Peptides 1996, 62:29-35
29. Holthuis J, Janssen E, Van Riel M, Martens G: Molecular probing of the secretory pathway in peptide hormone producing cells. J Cell Sci 1995, 108:3295-3305
30. Braks JAM, Broers CAM, Danger JM, Martens GJM: Structural organization of the gene encoding the neuroendocrine chaperone 7B2. Eur J Biochem 1996, 236:60-67
31. Martens GJM, Bussemakers MJG, Ayoubi TAY, Jenks BG: The novel pituitary polypeptide 7B2 is a highly conserved protein coexpressed with proopiomelanocortin. Eur J Biochem 1989, 181:75-79
32. Sigafoos J, Chestnut WG, Merril BM, Taylor LCE, Diliberto EJ, Viveros OH: Novel peptides from adrenomedullary chromaffin vesicles. J Anat 1993, 183:253-264
33. Vos MD, Jones JE, Treston AM: Human peptidylglycine alpha-amidating monooxygenase transcripts derived by alternative mRNA splicing of an unreported exon. Gene 1995, 163:307-311
34. Vos MD, Scott FM, Iwai N, Treston AM: Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. J Cell Biochem 1996, 27:1-12
35. Huttner WB, Natori S: Helper proteins for neuroendocrine secretion. Curr Biol 1995, 5:242-245
36. Eib DW, Martens GJM: A novel transmembrane protein with epidermal growth factor and follistatin domains expressed in the hypothalamo-hypophyssial axis of Xenopus laevis. J Neurochem 1996, 67:1047-1055
37. Romijn J, Erkens-Schulze S, Schröder F: Perspectives of the use of tissue culture models as an alternative to human prostate cancer xenografts in nude mice. Contrib Oncol 1996, 51:209-231
38. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG: CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996, 56:3042-3046
39. + cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996, 65:85-89
40. van Weerden WM, de Ridder CMA, Verdaasdonk CL, Romijn JC, Van der Kwast TH, Schröder, Van Steenbrugge GJ: Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996, 149:1055-1062
41. Noordzij MA, van Weerden WM, van der Kwast TH, Abrahamsson P-A, Gershagen S, Schröder FH, Van Steenbrugge GJ: Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1996, 149:859-871
42. van Steenbrugge GJ, van Weerden WM, de Ridder CMA, van der Kwast T, Schroeder FH: Development and application of prostatic xenograft models for the study of human cancer. Sex Hormones Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Edited by Motta M, Serio M. Amsterdam, Elsevier, 1994, pp 11-22
43. van Steenbrugge G, Groen M, de Jong F, Schröder F: The use of steroid-containing silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. Prostate 1984, 5:639-647
44. Holthuis J, Jansen E, Martens G: Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway. Biol Chem 1996, 271:17755-17760
45. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991, 39:741-748
46. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-ciloroform extraction. Anal Biochem 1987, 162:156-159
47. Ruizeveld de Winter JA, van Weerden WM, Faber PW, Van Steenbrugge GJ, Trapman J, Brinkmann AO, Van der Kwast TH: Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82. Endocrinology 1992, 131:3045-3050
48. Isaacs J, Coffey D: Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989, 2:33-50